IN8bio Reports Median Overall Survival of 20.9 Months in Newly Diagnosed Glioblastoma Patients Receiving Repeat-Dose Gamma-Delta T Cell Therapy

A final analysis pooled data from two Phase 1/2 studies of the autologous genetically modified cell therapy in newly diagnosed glioblastoma patients.

Key Points

  • IN8bio reported median overall survival of 20.9 months in newly diagnosed glioblastoma patients receiving repeat doses of its autologous gamma-delta T cell therapy, compared with 13.2 months in a standard-of-care control group.
  • Half of repeat-dose patients were alive at two years versus 10% of control patients, and median progression-free survival was 13.0 months versus 6.6 months.
  • Across both Phase 1/2 studies, no cytokine release syndrome, ICANS, major infections, or treatment-related serious adverse events were observed.

IN8bio, a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer and autoimmune diseases, announced updated clinical data from its INB-200 and INB-400 programs in newly diagnosed glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting in Philadelphia. INB-200/400 is an autologous genetically modified gamma-delta T cell therapy candidate in which a patient’s own gamma-delta T cells are given in repeat doses.

Across the INB-200 and INB-400 Phase 1/2 studies, patients receiving repeat doses achieved a final median overall survival of 20.9 months, compared with 13.2 months in the standard-of-care control group, and a median progression-free survival of 13.0 months versus 6.6 months. As of October 30, 2026, 50% of repeat-dose patients (7 of 14) were alive at two years, compared with 10% of control patients (1 of 10). These outcomes were observed despite a lower proportion of repeat-dose patients having undergone total surgical resection: 43%, versus 80% in the control group.

IN8bio described the safety profile as favorable, with no observed cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), major infections, or treatment-related serious adverse events across both studies. No treatment-related deaths were reported.

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence of γδ T cells in patients receiving multiple doses. Importantly, across our clinical experience, we have not observed any CRS, ICANS, major infections or treatment-related serious adverse events. These data continue to underscore the potential of γδ T cell-based therapies to provide meaningful clinical benefit for patients.”

Study Details

The results were presented on November 14, 2026 during the Clinical Trials Oral Abstracts Session II in a presentation titled, “INB-200/400: Final Phase 1/2 Study Results and A.I. based Deep Correlative Analysis of Gene-Modified Autologous Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma (GBM) Patients.” The analysis included 17 patients treated across the University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Moffitt Cancer Center, and the Cleveland Clinic.

Among repeat-dose patients, those in the INB-200 dose level 1 cohort had a median progression-free survival of 16.1 months and median overall survival of 21.1 months, with 5 of 10 alive at two years. The INB-400 cohort had a median progression-free survival of 13.0 months and median overall survival of 20.9 months, with 2 of 4 alive at two years. Patients 007 and 014 passed away from cardiovascular events without progression; patients without progression who are no longer alive were not censored in this analysis.

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Discussion

Sign in to join the discussion.

Similar stories